Drugs / SURGICEL® Powder
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06608992 | Sep 2024 → Aug 2025 overdue | osteoarthritis, knee | Peking University Third Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SURGICEL Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06608992 ↗ |
| Route | Topical | “The SURGICEL® Powder will be sprayed in areas such as the posterior joint capsule, medial gap, lateral gap, suprapatellar pouch, and infrapatellar fat pad.” NCT06608992 ↗ |